News
Data reveal is promising for GSK's lung cancer drug ris-rez
The first data from GSK's international trial of B7-H3-targeted ADC ris-rez in small cell lung cancer back up earlier results from a Chinese study.
R&D
From reactive to predictive: How data is redefining pharma l...
Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight.
News
Cancer biotech Nouscom adds €120m, and other financings
A €120m Series D for Swiss biotech Nouscom will support trials of a Lynch syndrome vaccine, with Soufflé, Estuary, and Microbiotica also raising cash.
News
Novartis abandons Fabhalta trial in lupus nephritis
A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for Fabhalta to include lupus nephritis.
News
RNAi biotech City hauls in $200m in upsized IPO
City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
